🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
EXE
$EXEL
🔒 US EquitiesExelixis, Inc.
AVG HISTORICAL GAP
+0.85%
MAX GAP RECORD
-13.81%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $EXEL
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$EXEL
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Oct 29, 2026 Earnings Release 2026-10-29 (AFTER CLOSE (16:00)) |
+2.81%
|
| Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE) |
-6.67%
|
| May 05, 2026 Earnings Release 2026-05-05 (AFTER CLOSE) |
+7.34%
|
| Feb 10, 2026 Earnings Release 2026-02-10 (AFTER CLOSE) |
+1.12%
|
| Nov 04, 2025 Earnings Release 2025-11-04 (AFTER CLOSE) |
+5.54%
|
| Jul 28, 2025 Earnings Release 2025-07-28 (AFTER CLOSE) |
-13.81%
|
| May 13, 2025 Earnings Release 2025-05-13 (AFTER CLOSE) |
+10.01%
|
| Feb 11, 2025 Earnings Release 2025-02-11 (AFTER CLOSE) |
+1.19%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
5.3%
Bullish Gaps (9)
Bearish Gaps (5)
Neutral / Flat (1)
📖 Intelligence Summary
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗